A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3079514 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2018
Price : $35 *
At a glance
- Drugs LY 3079514 (Primary) ; LY 3079514 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 16 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 23 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 22 May 2015 Planned End Date changed from 1 Sep 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.